Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic Dosage Adjustment in Pediatric Oncology Patients With Febrile Neutropenia (DAR-ARC)
NCT06293677Phase 4Recruiting
- Sponsor
- Lausanne University Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2028
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of piperacillin + tazobactam, meropenem in febrile neutropenia (FN), sponsored by Lausanne University Hospital. Started Mar 2024; status: recruiting.
02
Drugs
piperacillin + tazobactammeropenem
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT06293677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06293677.